Login
$GRAL
$108.50 +$2.90 (2.75%) After hours

$GRAL 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Q3 Galleri® Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% to More Than 174,000

05 Aug 2026 8-K: Results of Operations and Financial Condition

NHS-Galleri and PATHFINDER 2 Study Results Presented at 2026 ASCO Annual Meeting Demonstrated Consistent Strong Performance and Clinical Utility for Galleri

22 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The Annual Meeting of Stockholders (“Annual Meeting”) of GRAIL, Inc. (the “Company”) was held on June 18, 2026. Of the 42,916,593 shares of the Company’s common stock entitled to vote at the Annual Meeting as of the April 22, 2026 record...

01 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

As you know, you are currently employed by GRAIL, Inc. (“GRAIL” or the “Company”). This Amended and Restated Offer Letter (this “Agreement”) is intended to update and memorialize certain terms of your employment, as set forth herein. As ...

05 May 2026 8-K: Results of Operations and Financial Condition

New Data From the NHS-Galleri Trial and PATHFINDER 2 Study to be Presented at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

19 Feb 2026 8-K: Results of Operations and Financial Condition; Other Events

MENLO PARK, Calif. — Feb. 19, 2026 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2025 a...

12 Jan 2026 8-K: Results of Operations and Financial Condition

44th Annual J.P. Morgan Healthcare Conference January 12, 2026 1 Bob Ragusa, Chief Executive Officer Josh Ofman, President

14 Nov 2025 8-K: Other Events

GRAIL, Inc., a Delaware corporation (the “Company”), proposes to issue and sell through Morgan Stanley & Co. LLC and TD Securities (USA) LLC, acting as principals or sales agents (each, a “Manager,” and collectively, the “Managers”), on ...

12 Nov 2025 8-K: Results of Operations and Financial Condition

MENLO PARK, Calif. — Nov. 12, 2025 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2025.

20 Oct 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 18, 2025, by and among GRAIL, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “I...

16 Oct 2025 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more

Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both (a) not material and (b) is the type that the registrant customarily and actually treats as private or confidential.

18 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

4925-7231-6736.9 376361.00008/9-11-25/arb/arb SUNNYVALE TOWN CENTER Grail, Inc. OFFICE LEASE SUNNYVALE TOWN CENTER SUNNYVALE OFFICE ACQUISITION, LLC, a Delaware limited liability company, as Landlord, and GRAIL, INC., a Delaware corporat...

12 Aug 2025 8-K: Results of Operations and Financial Condition

MENLO PARK, Calif. — August 12, 2025 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2025.

30 May 2025 8-K: Submission of Matters to a Vote of Security Holders

The Annual Meeting of Stockholders (“Annual Meeting”) of GRAIL, Inc. (the “Company”) was held on May 29, 2025. Of the 35,296,858 shares of the Company’s common stock entitled to vote at the Annual Meeting as of the March 31, 2025 record ...

16 May 2025 8-K: Departure/Election of Directors or Officers; Compensation

As you know, you are currently employed by GRAIL, LLC (“GRAIL” or the “Company”). This Amended and Restated Offer Letter (this “Agreement”) is intended to update and memorialize certain terms of your employment, as set forth herein. This...

13 May 2025 8-K: Results of Operations and Financial Condition

MENLO PARK, Calif. — May 13, 2025 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025.

20 Feb 2025 8-K: Results of Operations and Financial Condition

MENLO PARK, Calif. — Feb. 20, 2025 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 a...

15 Jan 2025 8-K: Results of Operations and Financial Condition

43rd Annual J.P. Morgan Healthcare Conference Bob Ragusa, CEO January 2025 CONFIDENTIAL & PROPRIETARY 1

12 Nov 2024 8-K: Results of Operations and Financial Condition

MENLO PARK, Calif. — Nov. 12, 2024 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter 2024.

22 Oct 2024 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

MENLO PARK, Calif. – Oct. 21, 2024 – GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective imm...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support